Publication: Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study
Issued Date
2021-10-01
Resource Type
ISSN
13990012
09020063
09020063
Other identifier(s)
2-s2.0-85115321900
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Transplantation. Vol.35, No.10 (2021)
Suggested Citation
Yoshihiko Watarai, Romina Danguilan, Concesa Casasola, Shen Shin Chang, Prajej Ruangkanchanasetr, Terence Kee, Hin Seng Wong, Takashi Kenmochi, Angel Joaquin Amante, Kuo Hsiung Shu, Atiporn Ingsathit, Peter Bernhardt, Maria Pilar Hernandez-Gutierrez, Duck Jong Han, Myoung Soo Kim Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study. Clinical Transplantation. Vol.35, No.10 (2021). doi:10.1111/ctr.14415 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77813
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study
Other Contributor(s)
Ramathibodi Hospital
Fujita Health University Hospital
National Kidney and Transplant Institute Philippines
Asan Medical Center
Singapore General Hospital
Japanese Red Cross Nagoya Daini Hospital
Yonsei University College of Medicine
Novartis International AG
Phramongkutklao College of Medicine
Veterans General Hospital-Taichung Taiwan
National Cheng Kung University College of Medicine
Fujita Health University Hospital
National Kidney and Transplant Institute Philippines
Asan Medical Center
Singapore General Hospital
Japanese Red Cross Nagoya Daini Hospital
Yonsei University College of Medicine
Novartis International AG
Phramongkutklao College of Medicine
Veterans General Hospital-Taichung Taiwan
National Cheng Kung University College of Medicine
Abstract
Objective: We analyzed the efficacy and safety of an everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolic acid with standard-exposure CNI (MPA+sCNI) regimen in Asian patients from the TRANSFORM study. Methods: In this 24-month, open-label study, de novo kidney transplant recipients (KTxRs) were randomized (1:1) to receive EVR+rCNI or MPA+sCNI, along with induction therapy and corticosteroids. Results: Of the 2037 patients randomized in the TRANSFORM study, 293 were Asian (EVR+rCNI, N = 136; MPA+sCNI, N = 157). At month 24, EVR+rCNI was noninferior to MPA+sCNI for the binary endpoint of estimated glomerular filtration rate (eGFR) < 50 ml/min/1.73 m2 or treated biopsy-proven acute rejection (27.0% vs. 29.2%, P =.011 for a noninferiority margin of 10%). Graft loss and death were reported for one patient each in both arms. Mean eGFR was higher in EVR+rCNI versus MPA+sCNI (72.2 vs. 66.3 ml/min/1.73 m2, P =.0414) even after adjusting for donor type and donor age (64.3 vs. 59.3 ml/min/1.73 m2, P =.0582). Overall incidence of adverse events was comparable. BK virus (4.4% vs. 12.1%) and cytomegalovirus (4.4% vs. 13.4%) infections were significantly lower in the EVR+rCNI arm. Conclusion: This subgroup analysis in Asian de novo KTxRs demonstrated that the EVR+rCNI versus MPA+sCNI regimen provides comparable antirejection efficacy, better renal function, and reduced viral infections (NCT01950819).